# Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal Cancer

> **NCT03038217** · PHASE3 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Rectal Cancer, Adenocarcinoma
- Neoadjuvant Chemoradiation

## Interventions

- **DRUG:** Capecitabine +/- Oxaliplatin
- **PROCEDURE:** local resection
- **PROCEDURE:** radical resection
- **OTHER:** No adjuvant chemotherapy

## Key facts

- **NCT ID:** NCT03038217
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02
- **Primary completion:** 2020-12
- **Final completion:** 2021-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2017-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03038217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03038217, "Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03038217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*